Baidu
map

STM:治疗丙肝,过敏症药物显神通

2015-04-10 佚名 生物谷

近日一项来自国立卫生研究院的研究结果表明,治疗过敏症状的药物盐酸氯环嗪(CCZ)或许可以抑制丙肝小鼠机体中丙型肝炎病毒的活性,相关研究刊登于国际杂志Science Translational Medicine,这种药物或许可以被用于进行丙肝患者的治疗。丙肝病毒(HCV)可以引发机体肝脏炎症,经常会导致严重的并发症,比如肝硬化等;HCV的早期诊断和治疗可以有效抑制患者的肝脏损伤,目前有许多可治疗HC



近日一项来自国立卫生研究院的研究结果表明,治疗过敏症状的药物盐酸氯环嗪(CCZ)或许可以抑制丙肝小鼠机体中丙型肝炎病毒的活性,相关研究刊登于国际杂志Science Translational Medicine,这种药物或许可以被用于进行丙肝患者的治疗。

丙肝病毒(HCV)可以引发机体肝脏炎症,经常会导致严重的并发症,比如肝硬化等;HCV的早期诊断和治疗可以有效抑制患者的肝脏损伤,目前有许多可治疗HCV感染的药物,但价格都比较昂贵。

研究者T. Jake Liang博士表示,尽管丙肝可以治愈,但目前急需要有效且患者可负担得起的药物,盐酸氯环嗪或许就是一种潜在的候选药物来减缓HCV患者的疾病症状。我们发现盐酸氯环嗪可以通过干扰病毒进入人类肝脏细胞的能力来阻断HCV的早期感染(人类的肝脏细胞移植入小鼠中进行研究),而且预后也同常见的抗病毒药物相类似,且没有任何药物副作用。

利用这种创新性的高通量筛选技术,研究者就发现盐酸氯环嗪或许是丙肝的潜在抑制药物,下一步研究者将研究该药物如何影响人类机体的HCV,盐酸氯环嗪当前用于治疗过敏症,后期当研究者阐明盐酸氯环嗪的安全性和有效性后,该药物或许就可以用于治疗丙肝患者的疾病了。

最后研究者Griffin P. Rodgers指出,盐酸氯环嗪疗法或许最终会为丙肝患者提供一种可负担得起的药物治疗模式,尤其是对那些丙肝感染非常普遍的高发资源缺乏区域将无疑是一大福利和帮助。

原始出处:


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1677954, encodeId=1a5d16e7954fd, content=<a href='/topic/show?id=29a8168130f' target=_blank style='color:#2F92EE;'>#STM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16813, encryptionId=29a8168130f, topicName=STM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Sep 16 03:57:00 CST 2015, time=2015-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21150, encodeId=f05d21150d1, content=相信可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68151621385, createdName=leexiaohui, createdTime=Tue Apr 14 16:19:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21151, encodeId=240b2115153, content=我也在关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68151621385, createdName=leexiaohui, createdTime=Tue Apr 14 16:19:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21138, encodeId=cb762113892, content=持质疑态度, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=lecoo, createdTime=Tue Apr 14 11:53:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516437, encodeId=952a151643e25, content=<a href='/topic/show?id=0c06940668a' target=_blank style='color:#2F92EE;'>#过敏症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94066, encryptionId=0c06940668a, topicName=过敏症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=def310968681, createdName=ms1948154235210413, createdTime=Sun Apr 12 06:57:00 CST 2015, time=2015-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20505, encodeId=9b0a2050575, content=可以吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Sat Apr 11 23:06:00 CST 2015, time=2015-04-11, status=1, ipAttribution=)]
    2015-09-16 仁医06
  2. [GetPortalCommentsPageByObjectIdResponse(id=1677954, encodeId=1a5d16e7954fd, content=<a href='/topic/show?id=29a8168130f' target=_blank style='color:#2F92EE;'>#STM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16813, encryptionId=29a8168130f, topicName=STM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Sep 16 03:57:00 CST 2015, time=2015-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21150, encodeId=f05d21150d1, content=相信可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68151621385, createdName=leexiaohui, createdTime=Tue Apr 14 16:19:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21151, encodeId=240b2115153, content=我也在关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68151621385, createdName=leexiaohui, createdTime=Tue Apr 14 16:19:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21138, encodeId=cb762113892, content=持质疑态度, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=lecoo, createdTime=Tue Apr 14 11:53:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516437, encodeId=952a151643e25, content=<a href='/topic/show?id=0c06940668a' target=_blank style='color:#2F92EE;'>#过敏症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94066, encryptionId=0c06940668a, topicName=过敏症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=def310968681, createdName=ms1948154235210413, createdTime=Sun Apr 12 06:57:00 CST 2015, time=2015-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20505, encodeId=9b0a2050575, content=可以吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Sat Apr 11 23:06:00 CST 2015, time=2015-04-11, status=1, ipAttribution=)]
    2015-04-14 leexiaohui

    相信可以

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1677954, encodeId=1a5d16e7954fd, content=<a href='/topic/show?id=29a8168130f' target=_blank style='color:#2F92EE;'>#STM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16813, encryptionId=29a8168130f, topicName=STM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Sep 16 03:57:00 CST 2015, time=2015-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21150, encodeId=f05d21150d1, content=相信可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68151621385, createdName=leexiaohui, createdTime=Tue Apr 14 16:19:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21151, encodeId=240b2115153, content=我也在关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68151621385, createdName=leexiaohui, createdTime=Tue Apr 14 16:19:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21138, encodeId=cb762113892, content=持质疑态度, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=lecoo, createdTime=Tue Apr 14 11:53:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516437, encodeId=952a151643e25, content=<a href='/topic/show?id=0c06940668a' target=_blank style='color:#2F92EE;'>#过敏症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94066, encryptionId=0c06940668a, topicName=过敏症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=def310968681, createdName=ms1948154235210413, createdTime=Sun Apr 12 06:57:00 CST 2015, time=2015-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20505, encodeId=9b0a2050575, content=可以吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Sat Apr 11 23:06:00 CST 2015, time=2015-04-11, status=1, ipAttribution=)]
    2015-04-14 leexiaohui

    我也在关注

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1677954, encodeId=1a5d16e7954fd, content=<a href='/topic/show?id=29a8168130f' target=_blank style='color:#2F92EE;'>#STM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16813, encryptionId=29a8168130f, topicName=STM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Sep 16 03:57:00 CST 2015, time=2015-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21150, encodeId=f05d21150d1, content=相信可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68151621385, createdName=leexiaohui, createdTime=Tue Apr 14 16:19:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21151, encodeId=240b2115153, content=我也在关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68151621385, createdName=leexiaohui, createdTime=Tue Apr 14 16:19:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21138, encodeId=cb762113892, content=持质疑态度, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=lecoo, createdTime=Tue Apr 14 11:53:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516437, encodeId=952a151643e25, content=<a href='/topic/show?id=0c06940668a' target=_blank style='color:#2F92EE;'>#过敏症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94066, encryptionId=0c06940668a, topicName=过敏症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=def310968681, createdName=ms1948154235210413, createdTime=Sun Apr 12 06:57:00 CST 2015, time=2015-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20505, encodeId=9b0a2050575, content=可以吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Sat Apr 11 23:06:00 CST 2015, time=2015-04-11, status=1, ipAttribution=)]
    2015-04-14 lecoo

    持质疑态度

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1677954, encodeId=1a5d16e7954fd, content=<a href='/topic/show?id=29a8168130f' target=_blank style='color:#2F92EE;'>#STM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16813, encryptionId=29a8168130f, topicName=STM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Sep 16 03:57:00 CST 2015, time=2015-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21150, encodeId=f05d21150d1, content=相信可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68151621385, createdName=leexiaohui, createdTime=Tue Apr 14 16:19:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21151, encodeId=240b2115153, content=我也在关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68151621385, createdName=leexiaohui, createdTime=Tue Apr 14 16:19:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21138, encodeId=cb762113892, content=持质疑态度, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=lecoo, createdTime=Tue Apr 14 11:53:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516437, encodeId=952a151643e25, content=<a href='/topic/show?id=0c06940668a' target=_blank style='color:#2F92EE;'>#过敏症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94066, encryptionId=0c06940668a, topicName=过敏症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=def310968681, createdName=ms1948154235210413, createdTime=Sun Apr 12 06:57:00 CST 2015, time=2015-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20505, encodeId=9b0a2050575, content=可以吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Sat Apr 11 23:06:00 CST 2015, time=2015-04-11, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1677954, encodeId=1a5d16e7954fd, content=<a href='/topic/show?id=29a8168130f' target=_blank style='color:#2F92EE;'>#STM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16813, encryptionId=29a8168130f, topicName=STM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Sep 16 03:57:00 CST 2015, time=2015-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21150, encodeId=f05d21150d1, content=相信可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68151621385, createdName=leexiaohui, createdTime=Tue Apr 14 16:19:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21151, encodeId=240b2115153, content=我也在关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68151621385, createdName=leexiaohui, createdTime=Tue Apr 14 16:19:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21138, encodeId=cb762113892, content=持质疑态度, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=lecoo, createdTime=Tue Apr 14 11:53:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516437, encodeId=952a151643e25, content=<a href='/topic/show?id=0c06940668a' target=_blank style='color:#2F92EE;'>#过敏症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94066, encryptionId=0c06940668a, topicName=过敏症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=def310968681, createdName=ms1948154235210413, createdTime=Sun Apr 12 06:57:00 CST 2015, time=2015-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20505, encodeId=9b0a2050575, content=可以吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Sat Apr 11 23:06:00 CST 2015, time=2015-04-11, status=1, ipAttribution=)]
    2015-04-11 MedSci客户端网友

    可以吗?

    0

相关资讯

新药Viekira Pak——丙肝患者的福音

美国食品药品监督管理局近日批准了联合口服药物Viekira Pak上市。Viekira Pak可以用于治疗丙肝病毒(HCV)基因1型的患者,它低廉的价格使得患者和医生在sofosbuvir和ledipasvir/sofosbuvir药物之外又有了另一种选择。HCV治疗包括3种新药(ombitasvir, paritaprevir, and dasabuvir))以及利托那韦,其中利托那韦会升par

全国爱肝日:丙肝或成为下一个癌症的主要诱因

今日是第15个全国爱肝日。今年活动主题是“预防丙肝,防患于未然。”重庆市肿瘤医院医院专家提醒,近年来丙肝发病率的持续上升,可能会成为下一个导致肝癌的主要诱因,需引起关注。   饮酒无度,慢性丙肝发展成肝癌晚期    今年50岁的贺先生,家住沙坪坝区,是一家企业的营销经理,由于工作应酬,他从20多岁开始,几乎每天晚上都是在酒桌上和娱乐场所度过的,一天

抗丙肝革命性新药背后的“难题”(图)

丙肝病毒称得上一种隐形杀手,它能将肝脏纤维化,让人们在不知不觉中日渐消瘦,等到猛然发觉身体里潜伏数十年的病毒时,往往已病入膏肓。更可怕的是,它还可能趁着人们不知情时,传染给身边的亲友。目前,国内已有对抗这种病毒的方法,可是其副作用大,让患者有苦难言。可喜的是,国外业已研发出克制病毒且副作用小的良药,也有一些国家在生产廉价的仿制药。但这些似乎与眼下国内数以千万计的患者无关。因为药品管理制

丙肝治疗药物专利因缺乏创新性和创造性步骤在印度遭拒

印度专利管理局驳回了吉利德公司治疗丙肝的药物的专利申请,此举受到仿制药支持者的欢迎,因为这是一种极大降低丙肝治疗成本的方式。过去一年,丙肝见证了极昂贵的药物的出现。印度专利管理局的决定表明如果专利申请没有充足的新颖性并缺乏创造性步骤,印度法律条款将禁止授予专利。 驳回裁定称,丙肝是流行病,影响了全世界1.7亿人口,印度就有1800万。其他来源显示的数据更高。 驳回裁定称医药获取及知识组织(I-MA

丙肝治疗的突破:谁在受伤,谁在狂欢

此前新康界报道了艾伯维的丙肝新药KirVieaPak对吉利德的索菲布韦的冲击。吉利德的股票价格,在FDA批准消息后,已经接连3天下滑。丙肝治疗药物市场,未来竞争白热化已经是铁定的事情。 近日,汤森路透发表丙肝治疗进展报告,总结了近年来的丙肝治疗变迁,同时预测了丙肝用药市场,将是未来增长快速的一个领域,这一点与此前Evaluate Pharma发布的一份报告不谋而合。Evaluate Pharma

LANCET:Sofosbuvir联合利巴韦林可有效治疗 HCV、HIV 共感染患者

尽管不含干扰素的治疗方案已经被批准治疗HIV和2、3型HCV的共感染患者,但是以干扰素为基础的治疗方案对HIV和1、4型HCV型共感染患者来说仍然是的一个常用的选择。然而该方案由于其显著的临床毒性、与抗逆转录病毒药物的相互作用限制了该方案的应用。法国巴黎圣路易斯医院的研究者在 LANCET 2月3日在线发表了一文评估不使用干扰素的情况下、sofosbuvir联合利巴韦林治疗HIV/HCV共感染患者

Baidu
map
Baidu
map
Baidu
map